The study is a randomized, double-blind, placebo-controlled phase 2 trial evaluating the efficacy and safety of LEVI-04 in patients with knee osteoarthritis.[1] LEVI-04 was well tolerated in patients.[1] The drug has shown significant improvement in knee pain and function.[1] Primary measures include change in WOMAC pain subscale and WOMAC physical function subscale through 17 weeks.[1] Patients had to have confirmed KL grade ≥2 osteoarthritis of the knee according to the radiographic and clinical criteria of the American College of Rheumatology.[1] The target knee had a pain score ≥20 out of 50 on the WOMAC WOMAC subscale at screening and randomization.[1] The results support supplementation of endogenous p75NTR in the treatment of osteoarthritis.[1]